2026 Italian Guidelines: Management of Adult Postoperative Hypoparathyroidism

Full title: Italian Guidelines for the Management of Adult Postoperative Hypoparathyroidism, issued by the Italian Society of Endocrinology (SIE), published in Journal of Endocrinological Investigation, 2026 Core positioning: National multidisciplinary guideline covering risk stratification, early postoperative screening, transient vs permanent hypoparathyroidism, conventional calcium/active vitamin D therapy, rhPTH(1-84) add-on treatment, long-term organ complication surveillance. Distinguishes transient (self-recovering within 6–12 months) and permanent postoperative hypoparathyroidism (PoHypoPT), highlights avoiding over-treatment and hypercalciuria-related renal injury; aligned with ESE chronic hypoparathyroidism recommendations and compatible with prior thyroid interventional statement (NASIT 2026).

1. Definition & Classification

Postoperative hypoparathyroidism mostly arises from devascularization or accidental resection of parathyroid glands during thyroidectomy, central neck dissection or parathyroid surgery.

1. Transient PoHypoPT: low PTH + hypocalcemia after neck surgery, parathyroid function recovers within 6–12 months. The majority of post-thyroidectomy hypocalcemia belongs to this category.
2. Permanent PoHypoPT: persistent hypocalcemia with inappropriately low PTH, requiring ongoing medication >12 months after surgery.

Diagnostic criteria: albumin-adjusted total calcium / ionized calcium low, together with low or non-suitable normal PTH; hypomagnesemia must be excluded and corrected first.

2. Preoperative Risk Stratification & Surgical Prevention

High-risk patients: total thyroidectomy, central neck lymphadenectomy, reoperative neck surgery, substernal goiter surgery.

• Intraoperative strategies: parathyroid identification, ICG angiography, near-infrared autofluorescence (NIRAF), parathyroid autotransplantation for devascularized glands.
• Preoperative correction of vitamin D deficiency and hypomagnesemia reduces postoperative hypocalcemia severity.

3. Early Postoperative Screening & Acute Management (0–30 days)

Screening protocol

Check PTH at 12–24h after surgery + albumin-adjusted calcium on POD1.

• PTH <10 pg/mL: high risk for hypocalcemia, start close monitoring and oral prophylaxis.

Acute hypocalcemia treatment

1. Severe symptomatic hypocalcemia (corrected calcium <1.9 mmol/L / <7.5 mg/dL, tetany, laryngospasm, arrhythmia) 10% calcium gluconate IV slow bolus, followed by continuous calcium infusion. Correct hypomagnesemia concurrently.
2. Asymptomatic mild hypocalcemia: oral calcium carbonate (elemental calcium 1000–3000 mg/d, split doses) + calcitriol 0.25–0.5 μg daily.

Calcium citrate preferred in patients with achlorhydria, PPI long-term use or gastrointestinal malabsorption.

4. Chronic Medical Management (after 1 month)

First-line conventional therapy

Oral elemental calcium + active vitamin D (calcitriol / alfacalcidol). Treatment target:

• Corrected serum calcium: low-normal reference range (2.0–2.2 mmol/L), avoid normocalcemia upper limit.
• Serum phosphate: within normal range.
• Calcium-phosphate product < 4.4 mmol²/L², minimize urinary calcium excretion.

Key principle: avoid overcorrection; hypercalciuria causes nephrolithiasis, nephrocalcinosis and renal impairment, the most common long-term adverse outcome.

Second-line: rhPTH(1-84) recombinant human parathyroid hormone (add-on therapy)

✅ Indications (when calcium + active vitamin D fail):

1. Poor calcium control despite optimized conventional regimen;
2. Recurrent nephrolithiasis / progressive nephrocalcinosis;
3. Severe gastrointestinal intolerance to high-dose calcium supplements;
4. Persistent disabling symptoms (fatigue, paresthesia) with acceptable serum calcium.

rhPTH(1-84) is add-on, not full replacement; calcium and active vitamin D doses should be reduced after initiation. Monitoring: serum calcium within 3–7 days after dose titration.

Magnesium management

Hypomagnesemia impairs PTH secretion and end-organ calcium responsiveness; serum magnesium maintained within normal range.

5. Distinguish Transient vs Permanent PoHypoPT & Tapering Strategy

• For transient PoHypoPT: attempt gradual tapering of calcitriol and calcium after 3 months; reassess PTH/calcium every 1–3 months up to 12 months.
• If parathyroid function recovers, medications can be fully discontinued.
• If still dependent on therapy at 12 months: diagnosed as permanent PoHypoPT, start lifelong long-term surveillance.

6. Long-term Surveillance for Permanent PoHypoPT

1. Biochemistry: serum calcium, phosphate, magnesium, creatinine/eGFR, 24h urinary calcium at baseline; every 6–12 months once stable.
2. Renal imaging: renal ultrasound at diagnosis, repeat every 2–5 years to screen nephrocalcinosis and stones.
3. Bone assessment: DXA bone mineral density; PoHypoPT patients often have higher BMD, but vertebral fracture screening if clinical indication.
4. Other screening: ophthalmologic exam for cataract, brain CT only for symptomatic basal ganglia calcification.

7. Special Populations

1. Elderly patients: lower calcium target, cautious dose titration, avoid hypercalciuria and renal injury; medication reconciliation for drugs altering calcium/magnesium.
2. Pregnancy / lactation: prefer conventional calcium + active vitamin D; rhPTH(1-84) not recommended routinely in pregnancy.
3. Coexisting CKD: stricter calcium and phosphate targets, avoid high active vitamin D doses, nephrology co-management.

8. Common Pitfalls

1. ❌ Targeting serum calcium to mid/upper normal: increases hypercalciuria and renal calcification risk.
2. ❌ Ignoring 24h urinary calcium monitoring: normal serum calcium can coexist with harmful hypercalciuria.
3. ❌ Continuing high-dose supplementation indefinitely without annual tapering attempt for transient cases.
4. ❌ Using native vitamin D (cholecalciferol/ergocalciferol) as primary therapy; native vitamin D alone is insufficient for PoHypoPT, only for baseline vitamin D repletion.

9. Evidence Limitations

1. Real-world long-term safety of rhPTH(1-84) in Italian cohorts continues to accumulate; long-term fracture risk data remains limited.
2. No unified international consensus on optimal urinary calcium threshold.
3. Access and reimbursement of rhPTH(1-84) remains a practical barrier.

10. Cross alignment with previous guideline series

1. This 2026 Italian guideline: postoperative hypoparathyroidism after neck surgery, transient/permanent differentiation, rhPTH add-on and renal complication surveillance.
2. NASIT 2026 thyroid embolization statement: TAE may carry risk of parathyroid ischemia; this guideline defines the management pathway if PoHypoPT occurs after thyroid intervention.
3. 2026 SGO/SAGES endometrial cancer & bariatric surgery statement: addresses obesity and metabolic disease; this guideline focuses on neck-surgery related parathyroid deficiency and mineral metabolism.

Disclaimer: This summary is for academic study only, not for direct clinical prescription. Management of postoperative hypoparathyroidism requires multidisciplinary endocrine/neck surgery evaluation and serial biochemical monitoring